SEOUL, South Korea, Feb. 18, 2026 /PRNewswire/ — Despite the ongoing cold winter season, South Korea continues to attract interest from inbound travelers, fueled by a variety of seasonal events and activities available during the winter months. Reflecting this trend, digital travel platform Agoda has revealed the most searched destinations and preferred winter activities among international travelers visiting South Korea.

According to Agoda’s accommodation search data, Seoul ranked as the top destination among inbound travelers, followed by Jeju, Busan, Incheon, and Sokcho, completing the top five.

Seoul’s appeal was driven in part by the “Seoul Winter Festa,” which features a range of seasonal attractions, such as the “Seoul Light Gwanghwamun,” the “Seoul Plaza Ice Skating Rink,” “Gwanghwamun Market,” and “Seoul Light DDP.” According to the Seoul Metropolitan Government, the festival recorded an all-time high of nearly 11 million visitors, including both domestic and inbound travelers, reinforcing Seoul’s popularity as a winter destination.

Interest from international travelers is also expanding beyond major metropolitan areas. Sokcho, known for its local markets, fresh seafood, sweet and sour chicken, and other culinary delicacies, recorded a 37% year-on-year increase in accommodation searches according to Agoda. This may indicate a growing interest in secondary destinations among inbound travelers beyond the primary travel hubs.

When it comes to source markets, Japanese travelers emerged as the top market expressing travel interest to South Korea in the winter season, according to accommodation searches made on Agoda. Taiwan ranked second, followed by China, Hong Kong, and Thailand. Thailand newly entered the top five this year, while China recorded the highest year-on-year growth in travel interest among the top five source markets at 56%, potentially influenced by the visa-free entry policy for Chinese group travelers.

When looking at the winter activity preferences, Agoda’s activities booking data shows that tickets to major theme parks and tourist attractions in Seoul and Busan ranked highest, such as Lotte World and N Seoul Tower Observatory. In addition, foreigner-exclusive tour passes, such as the Visit Busan Pass, and traditional wellness offerings such as SPA LAND Centum City and Aquafield Jimjilbang Spa & Sauna ranked among the top activities. These findings could point to an increasing preference for convenient all-in-one sightseeing options, alongside opportunities for rest and recovery during winter vacations.

Jay Lee, Regional Director, North Asia at Agoda, said, “South Korea offers an array of winter experiences, ranging from scenic snowscapes and delicious winter snacks to traditional jjimjilbangs that provide warmth during the colder months. Agoda’s data reflects a growing demand for experiences that integrate entertainment, convenience, and relaxation. In response, Agoda remains committed to providing competitive deals and a broad selection of accommodations, flights, and activities for both inbound and domestic travelers this winter season and beyond.”

Travelers planning trips within South Korea are encouraged to check out Agoda’s great value deals on over 6 million holiday properties, more than 130,000 flight routes, and over 300,000 activities and experiences that are available on the platform. The latest deals are available in the Agoda app or on agoda.com/deals.

CHENNAI, India, Feb. 18, 2026 /PRNewswire/ — Global enterprise software company Ramco Systems today announced its entry into the Agentic AI product segment with the launch of Chia, a conversational AI agent platform designed to redefine how enterprises engage with their customers. Chia is purpose-built for enterprises to reliably automate complex customer support interactions, reducing manual effort, response times, and operating costs, enabling businesses to deliver superior customer experiences at scale.

Chia helps enterprises automate complex customer support interactions with reliability and scale, reducing manual effort and response times while improving overall customer experience.

Part of Ramco’s new AI-driven task automation suite, rTask, Chia delivers enterprise–grade conversational Agents that goes beyond answering queries to reason, decide, and act, executing end-to-end workflows across enterprise systems. This platform empowers organizations to shift from ‘human-in-the-loop’ support models to a future of exception-based human involvement, where AI handles the heavy lifting. Chia does this by executing multi-step backend actions to resolve customer requests, integrating seamlessly with enterprise systems all while operating within defined goals, compliance policies, and guardrails.

At the heart of Chia is a no-code AI Agent Foundry that enables CX teams to design, configure, and deploy AI Agents using plain English instructions, without waiting for engineering cycles.

With Natural Language Workflow (NLW) capabilities, non-engineering teams can define AI logic such as refund eligibility, booking validations, or policy enforcement in simple English. The system then translates these rules into deterministic, action-taking AI behaviour, thereby preventing hallucinations. Organizations can deploy their first AI Agent in weeks, significantly accelerating time-to-value.

Abinav Raja, Managing Director, Ramco Systems, said, “Chia addresses a rapidly growing global market need for AI systems that are not just conversational, but truly agentic, capable of reasoning, acting, and delivering measurable outcomes. As our first AI-native product, Chia marks a significant milestone in Ramco’s transformation journey. It is the beginning of a broader roadmap, with many more AI-native innovations planned across our portfolio. This launch is aligned with our vision to transform our entire platform to be AI-native, embedding agentic intelligence into every product we build. We believe the future of enterprise software is agentic by design, autonomous, adaptive, and continuously evolving, and we are committed to leading that transformation.” 

Sandesh Bilagi, President & COO, Ramco Systems, said, “Customers today expect accuracy, speed, and seamless support across every touchpoint. Chia rises to this challenge by enabling enterprises to automate complex customer interactions with confidence and control. As Chia enables teams to deploy production–grade AI Agents in weeks, not months, organizations can modernize their support operations without lengthy implementation cycles, ultimately delivering faster and more consistent customer experiences.”

About Ramco Systems: 

Ramco Systems is a world-class enterprise software product/ platform provider disrupting the market with its multi-tenant cloud and mobile-based enterprise software, successfully driving innovation for over 25 years. Over the years, Ramco has maintained a consistent track record of serving 800+ customers globally with two million+ users and delivering tangible business value in Global Payroll, Aviation, Aerospace & Defense, and ERP. Ramco’s key differentiator is its innovative product development approach through its revolutionary enterprise application assembly and delivery platform. On the innovation front, Ramco is leveraging cutting-edge technologies around Artificial Intelligence, Machine Learning, RPA, and Blockchain, amongst others, to help organizations embrace digital transformation. 

For more information, please visit https://www.ramco.com/ai/conversational-ai

Follow Ramco on LinkedIn and stay tuned to https://www.ramco.com/ai/conversational-ai/blog

• Webull Connect is designed to provide Australian financial advisers access to multi-currency Australian, U.S. and Hong Kong markets from a single platform, enabling trade execution and portfolio management across multiple accounts.
• The launch marks Webull’s entry into the Australian wealth management segment.
• Webull’s high-tech, low-fee platform supports such advisers wishing to grow their margins while maintaining competitive pricing for their underlying clients.

SYDNEY, Feb. 18, 2026 /PRNewswire/ — Webull Securities (Australia) Pty Ltd (“Webull Australia”), a subsidiary of Webull Corporation (NASDAQ: BULL), the owner of the Webull trading platform, has today announced the launch of Webull Connect, a high-tech portfolio management and execution platform designed for the needs of Australian financial advisers.

With the launch of Webull Connect, Australian financial advisers now have access to a modern, digital-first platform that streamlines the management of multiple client accounts, including a centralised dashboard with visibility across portfolios, positions, and cash balances, designed to reduce complexity and achieve greater control over portfolio management.

The platform offers access to a range of international markets, including Australian, US and Hong Kong-listed equities, ETFs, and options, as well as 24/5 extended market hours to US markets, enabling advisers to act on global market movements throughout the Australian business day.

“International market access is the real differentiator,” said Rob Talevski, CEO of Webull Australia. “Client demand for global diversification is growing, and we strive to make it easy for advisers to deliver that. Combined with an intuitive, digital-first platform, backed by the global infrastructure of a Nasdaq-listed company, we’re introducing real competition to a market that we feel has been underserved for too long.”

The platform allows advisers to submit orders for a single instrument across multiple accounts, offering in-house execution, settlement and clearing while reducing manual work and minimising the risk of errors. Built-in FX functionality enables seamless trading across international markets, with clients able to hold and convert between AUD, USD, and HKD within the platform.

As an ASX market participant, Webull can facilitate bulk portfolio transfers of client holdings, making it simple for advisers to transition existing portfolios onto the platform.

Webull Connect is now available to Australian financial advisers and dealer groups. To connect with the Webull team, contact Jason.sivyer@webull-au.com.  

###

About Webull Australia

Webull Securities (Australia) Pty. Ltd. is a leading financial services provider, holding an Australian Financial Services Licence (AFSL 536980) and regulated by the Australian Securities and Investments Commission (‘ASIC’). As a trading participant of both the Australian Securities Exchange (‘ASX’) and Cboe Australia (‘Cboe’), and a principal member of the Stockbrokers and Investment Advisers Association, Webull strives to ensure the highest standards of service and security. Learn more at Webull.com.au.

About Webull

Webull Corporation (NASDAQ: BULL) owns and operates Webull, a leading digital investment platform built on next-generation global infrastructure. Through its global network of licensed brokerages, Webull offers investment services in 14 markets across North America, Asia Pacific, Europe, and Latin America. Webull serves more than 25 million registered users globally, providing retail investors with 24/7 access to global financial markets. Users can put investment strategies to work by trading global stocks, ETFs, options, futures, fractional shares, and digital assets through Webull’s trading platform, which seamlessly integrates market data and information, its user community, and investor education resources. Learn more athttps://www.webullcorp.com/ 

Media contact:
Cognito for Webull
webull@cognitomedia.com

MELBOURNE, Australia and INDIANAPOLIS, Feb. 18, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has submitted a marketing authorization application (MAA) in Europe for TLX101-Px (O-(2-[¹⁸F]fluoroethyl)-L-tyrosine, ¹⁸F-FET), its glioma (brain cancer) imaging candidate.

Telix has been preparing the European and U.S. regulatory packages for TLX101-Px concurrently, bringing forward the European submission to meet an agreed filing date while aligning with aspects of the U.S. Food and Drug Administration (FDA) package to support the additional application. The submission covers major European markets^[1]. Telix is seeking to expand patient access to advanced brain imaging through a broad clinical label, reflective of current clinical practice guidelines^[2]. Submission of the U.S. New Drug Application (NDA) will follow.

In Europe, positron emission tomography (PET) imaging of glioma with ¹⁸F-FET (FET-PET) is currently performed under physician-supervised use through hospital-based production at a limited number of sites. However, there is currently no generally available commercial product in Europe that ensures consistent quality and access for glioma imaging, an acute and immediate need^[3]. Telix aims to expand patient access to advanced imaging that can distinguish progressive or recurrent glioma from treatment-related changes in both adults and children, with potential for additional future indications. TLX101-Px is also being developed as a patient selection and response assessment tool for Telix’s glioblastoma therapy candidate TLX101-Tx (iodofalan ¹³¹I), which has been granted orphan drug designation in Europe and the U.S. and is the subject of the Phase 3 IPAX-BrIGHT trial in patients with recurrent glioblastoma, launching in multiple European countries^[4].

Philipp Lohmann, Group Leader Digital Translational Neuroimaging at Forschungszentrum Jülich research center in Germany, commented, “FET-PET imaging is already used in clinical practice in Europe for the evaluation of gliomas, and plays a critical role in treatment decision making. This applies particularly in the post-therapy setting, where conventional MRI^[5] alone can be limited in its ability to distinguish tumor progression from treatment-related changes. Having widespread access to TLX101-Px has potential to provide clinicians with greater biological insight, supporting more confident and timely management of patients with brain tumors.”

Kevin Richardson, Chief Executive Officer, Telix Precision Medicine, added, “We see a compelling opportunity in Europe to broaden access to authorized targeted radiopharmaceuticals for brain cancer imaging and therapy, and as such this submission is an important milestone for Telix. The strategic value of this submission is particularly relevant to establishing widespread glioma imaging as part of our corresponding therapeutic development program. We have been able to utilize aspects of our FDA package to expedite the European filing, which has been submitted in accordance with a pre-defined date agreed with the regulator, with the U.S. resubmission to follow.”

About glioma in Europe

In Europe, approximately 67,500 brain and central nervous system tumors are diagnosed every year^[6], with gliomas accounting for approximately 30% of these, and up to 80% of all malignant brain tumors^[7]. There is a critical unmet need to improve the diagnosis and management of gliomas, which are the most common primary brain tumors of the central nervous system, particularly in the post-treatment setting⁵. Conventional MRI imaging techniques have several limitations, including a lack of biological specificity, dependency on blood-brain barrier disruption, and an inherent inability to differentiate between tumor progression or treatment-related causes. This can yield inconclusive results and delay time-sensitive treatment decisions^[8]. With low survival rates and the need to make rapid decisions, precision imaging is paramount⁵. Subject to regulatory approval, TLX101-Px has the potential to address this need, enabling patients in Europe to receive greater clarity in their diagnosis and treatment decision making.

About TLX101-Px

TLX101-Px (O-(2-[¹⁸F]fluoroethyl)-L-tyrosine) is Telix’s PET imaging candidate for the characterization of glioma. TLX101-Px targets membrane transport proteins known as L-type amino acid transporters 1 and 2 (LAT1 and LAT2). This enables TLX101-Px to be potentially utilized as a complementary diagnostic agent to TLX101-Tx (iodofalan ¹³¹I), Telix’s LAT1-targeting investigational glioblastoma (GBM) therapy, currently under investigation in Telix’s IPAX-2^[9] and IPAX-BrIGHT⁶ studies. TLX101-Px and TLX101-Tx have not received a marketing authorization in any jurisdiction. In relevant European markets, the proposed brand name for TLX101-Px is “Pixlumi®”. Brand name and commercial launch are subject to final regulatory approval.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

Telix Investor Relations (Global)

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-Px and the planned BLA resubmission for TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

LONDON, Feb. 18, 2026 /PRNewswire/ — AML RightSource, the leading expert solutions provider of managed services and advisory, announced the formation of its International Advisory Board, chaired by Vesna McCreery.

The board is an independent body within AML RightSource’s global advisory structure, complementing the North America board. Bringing together practitioner-led expertise from the UK, Europe, APAC, and Australia, it will support the firm’s global expansion and strengthen its role as a trusted partner in preventing financial crime across banking, payments, crypto, and other sectors.

As financial crime grows more complex, the Board will help AML RightSource anticipate regulatory shifts, challenge norms, and refine service delivery. Its insight will help the firm meet clients’ evolving needs amid heightened scrutiny and operational demands.

Inaugural International Advisory Board

Dayna Bordin – Financial Crime Transformation Leader (Banking & Digital Assets)
Dayna brings over two decades of experience as a compliance practitioner, auditor, and consultant. She’s led major transformation programs at Barclays, Santander, and HSBC and now serves as UK MLRO at GSR. Dayna offers the Board deep expertise in large‑bank transformation, audit, and the evolving crypto regulatory ecosystem.

Matt Brown – Global Sanctions & Financial Crime Detection Expert
Matt is an industry-recognized leader in transaction screening, advancing sanctions, AML, and anti-terror detection. He’s delivered major technology transformations at institutions including RBS, Barclays, and HSBC, championing technology-led approaches that strengthen detection while reducing friction. He also contributes to the Wolfsberg Group.

John Fogarty – Senior Financial Crime Leader with APAC & Australian Expertise
John brings extensive experience from leadership roles in Singapore, Hong Kong, and Australia with UBS, HSBC, and the Commonwealth Bank of Australia. He brings strong insight into APAC regulatory expectations, regional supervisory environments, with transformational change and large-scale remediation experience.

Alan Ketley – Global AML Authority & Former Executive Secretary, Wolfsberg Group
Alan brings over 40 years of AML leadership across global institutions. As the first permanent Executive Secretary of the Wolfsberg Group, he helped shape industry thinking through practical, effectiveness-focused publications.

“We’re proud to welcome such distinguished leaders,” said Vesna McCreery, Chair, International Advisory Board. “Their experience is invaluable as AML RightSource expands its capabilities.”

“Our clients face increasing regulatory pressure in a dynamic environment,” added Steve Meirink, AML RightSource’s CEO. “This Board brings practitioner insight directly into our strategic decision‑making.”

AML RightSource – leading global provider of managed services and advisory for financial crime compliance. amlrightsource.com.